Unknown

Dataset Information

Fibroblast growth factor 21 may be a strong biomarker for renal outcomes: a meta-analysis.


ABSTRACT:

Background

Fibroblast growth factor 21 (FGF21) is deemed to play an important role in kidney outcomes, while the association between FGF21 and various kidney diseases remains largely unclear and inconsistent. Therefore, we conducted this meta-analysis to find out the role of FGF21 in various renal diseases.

Methods

The outcome indicator of our study was assessed by the pooled standard mean difference (SMD) with 95% confidence intervals (CIs) which were calculated by random-effect model analysis. The risk of bias was assessed by Non-Randomized Studies of Interventions (ROBINS-I) tool. Funnel plot combined with Egger's and Begg's tests was performed to estimate the publication bias that existed in the study.

Results

A total of 28 eligible studies with 19348 participants

SUBMITTER: Yong G 

PROVIDER: S-EPMC10071947 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature